GlucaGen Diagnostic Kit, Glucagon Newswire

GlucaGen Diagnostic Kit, Glucagon Newswire

Comprehensive Real-Time News Feed for GlucaGen Diagnostic Kit, Glucagon (generic).

Results 1 - 20 of 27 in GlucaGen Diagnostic Kit, Glucagon (generic)

  1. Back to school with diabetesRead the original story w/Photo

    Wednesday Aug 3 | MSN Healthy Living

    Parents of children with diabetes can set up an individual 504 Plan with the school to ensure safety and accessibility. Brooke Yost of St. Louis, Missouri, is starting seventh grade in style.

    Comment?

  2. Back to School With DiabetesRead the original story

    Wednesday Aug 3 | US News & World Report

    Parents of children with diabetes can set up an individual 504 Plan with the school to ensure safety and accessibility. Brooke Yost of St. Louis, Missouri, is starting seventh grade in style.

    Comment?

  3. Brief Insights: FDA approves Sanofi's next-gen diabetes treatment - iData InsightsRead the original story w/Photo

    Tuesday Aug 2 | PR Log

    The injectable drug Adlyxin has been approved to treat adults with type 2 diabetes, the U.S Food & Drug Administration says. The once-daily injection is to be used along with diet & exercise to improve patients' blood sugar levels MANHATTAN, N.Y. - Aug. 2, 2016 - PRLog -- FDA approves Sanofi's next-gen diabetes treatment The injectable drug Adlyxin has been approved to treat adults with type 2 diabetes, the U.S. Food and Drug Administration says.

    Comment?

  4. FDA OKs New Injectable Type 2 Diabetes MedicationRead the original story w/Photo

    Friday Jul 29 | MedicineNet

    The injectable drug Adlyxin has been approved to treat adults with type 2 diabetes , the U.S. Food and Drug Administration says. The FDA reviewed 10 clinical trials on the safety and effectiveness of Adlyxin.

    Comment?

  5. Adlyxin approved for type 2 diabetesRead the original story

    Thursday Jul 28 | UPI

    Adlyxin has been approved by the U.S. Food and Drug Administration to treat type 2 diabetes in adults, the agency said Thursday in a news release. As the FDA explained, Adlyxin is a "glucagon-like peptide-1 receptor agonist" -- a hormonal drug that helps control blood sugar.

    Comment?

  6. FDA Green Lights Sanofi''s Adlyxin to Help Treat Type 2 DiabetesRead the original story

    Wednesday Jul 27 | BioSpace

    Sanofi Receives FDA Approval of AdlyxinTM for Treatment of Adults with Type 2 Diabetes - AdlyxinTM is approved as LyxumiaA in more than 60 countries - /PRNewswire/ -- Sanofi announced today that the U.S. Food and Drug Administration approved AdlyxinTM , a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes. "The approval of Adlyxin reaffirms our continued commitment to addressing the challenges faced by people living with diabetes when trying to reach and maintain their individual blood glucose targets," said , Executive Vice President, Head, Global Diabetes & Cardiovascular Business Unit, Sanofi.

    Comment?

  7. Sanofi Receives FDA Approval Of Adlyxin For Treatment Of Adults With Type 2 DiabetesRead the original story

    Wednesday Jul 27 | BioSpace

    "The approval of Adlyxin reaffirms our continued commitment to addressing the challenges faced by people living with diabetes when trying to reach and maintain their individual blood glucose targets," said , Executive Vice President, Head, Global Diabetes & Cardiovascular Business Unit, Sanofi. "We are pleased with this approval, as it offers us the opportunity to continue helping patients treated with basal insulin who remain uncontrolled."

    Comment?

  8. Antidiabetic effects discovered in the appetite hormone CARTRead the original story w/Photo

    Jun 30, 2016 | PhysOrg Weblog

    The study shows that the appetite hormone CART not only controls the sensation of satiety, but it also helps increase insulin secretion and decrease glucagon production. CART is a hormone that has mainly been studied in the brain's centre for appetite control.

    Comment?

  9. Diabetic Coma Recovery: What You Need To KnowRead the original story w/Photo

    Jun 25, 2016 | Medical News Today

    In people with diabetes, a diabetic coma occurs when severe levels of either high or low uncontrolled blood sugar are not corrected. If treated quickly, a person will make a rapid recovery from a diabetic coma.

    Comment?

  10. American Diabetes Association Release: Bionic Pancreas Reduces...Read the original story

    Jun 14, 2016 | BioSpace

    Glucagon is a hormone produced by the pancreas that raises blood glucose and works together with insulin, which has the opposite effect, to tightly regulate blood glucose concentrations. Both glucagon and insulin production are impaired in people with type 1 diabetes.

    Comment?

  11. Bionic Pancreas Reduces Hypoglycemia with Automated Glucagon DeliveryRead the original story

    Jun 14, 2016 | Freshnews

    Delivering small doses of glucagon through an automated continuous glucose monitoring system can substantially reduce hypoglycemia in patients with type 1 diabetes, especially at night, according to a study presented at the American Diabetes Association's 76th Scientific Sessions at the Ernest N. Morial Convention Center in New Orleans. Glucagon is a hormone produced by the pancreas that raises blood glucose and works together with insulin, which has the opposite effect, to tightly regulate blood glucose concentrations.

    Comment?

  12. Eiger Biopharma Announces Positive Clinical Results Of Single...Read the original story

    Jun 13, 2016 | BioSpace

    Results were delivered by The study used a single ascending dose design to examine the pharmacokinetics, pharmacodynamics, and local tolerability of three escalating doses of subcutaneous exendin . Eight subjects suffering from PBH were enrolled and administered oral glucose tolerance tests with and without subcutaneous exendin .

    Comment?

  13. Eli Lilly Release: New Data Show Eli Lilly's Once-Weekly Trulicity...Read the original story w/Photo

    Jun 12, 2016 | BioSpace

    Eli Lilly Release: New Data Show Eli Lilly 's Once-Weekly Trulicity In Combination With Insulin Glargine Improves Glycemic Control In People With Type 2 Diabetes /PRNewswire/ -- New data from a completed Phase 3 trial show TrulicityA 1.5 mg significantly reduced hemoglobin A1c and body weight as an add-on to insulin glargine without increasing the risk of low blood sugar after 28 weeks compared to placebo plus insulin glargine. Trulicity is Eli Lilly and Company's once-weekly glucagon-like peptide-1 receptor agonist that is used along with diet and exercise for the treatment of type 2 diabetes.

    Comment?

  14. New Data Show Lillya s Once-Weekly Trulicity (dulaglutide) in...Read the original story w/Photo

    Jun 12, 2016 | Freshnews

    New data from a completed Phase 3 trial show Trulicity 1.5 mg significantly reduced hemoglobin A1c and body weight as an add-on to insulin glargine without increasing the risk of low blood sugar after 28 weeks compared to placebo plus insulin glargine. Trulicity is Eli Lilly and Company's once-weekly glucagon-like peptide-1 receptor agonist that is used along with diet and exercise for the treatment of type 2 diabetes.

    Comment?

  15. Eli Lilly and Company logo.Read the original story w/Photo

    Jun 9, 2016 | PR Newswire

    New Data Show Lilly's Once-Weekly TrulicityA in Combination with Insulin Glargine Improves Glycemic Control in People with Type 2 Diabetes /PRNewswire/ -- New data from a completed Phase 3 trial show Trulicity 1.5 mg significantly reduced hemoglobin A1c and body weight as an add-on to insulin glargine without increasing the risk of low blood sugar after 28 weeks compared to placebo plus insulin glargine. Trulicity is Eli Lilly and Company's once-weekly glucagon-like peptide-1 receptor agonist that is used along with diet and exercise for the treatment of type 2 diabetes.

    Comment?

  16. Pancreas procedure for Type 1 diabetesRead the original story w/Photo

    Jun 5, 2016 | Philly.com

    She recalls leaving her friend's house in Pennsylvania with her 2-year-old twins in the back of the car and heading back to her home in North Hanover, N.J. She vaguely remembers feeling a little confused, and a little lost. But the next thing she knew, she had run the car into a ditch, the police and ambulance arrived, and she was on her way to the hospital.

    Comment?

  17. Eiger Biopharma Announces First Patient Dosed In Phase 2 Multiple...Read the original story

    May 9, 2016 | BioSpace

    Exendin is a 31-amino acid peptide, which selectively targets and blocks glucagon like peptide-1 receptors, normalizing insulin secretion by the pancreas, and thereby reducing hypoglycemia. researchers have already demonstrated in proof-of-concept exploratory clinical studies with exendin that pharmacologic blockade of GLP-1 prevents hypoglycemia in post-bariatric surgical patients and may represent the first targeted medical treatment for patients with post-gastric bypass hypoglycemia.

    Comment?

  18. 2-Drug Combo Beats Conventional Diabetes MedsRead the original story w/Photo

    Mar 16, 2016 | News Max

    A two-drug combination has been found to beat convention medication, when it comes to managing diabetes, and also offers users a beneficial side effect: Greater weight loss. A multinational clinical trial led by University of Texas Southwestern Medical Center found that combining a new long-acting insulin with another drug improved glucose control in Type 2 diabetics and helped them shed pounds.

    Comment?

  19. Drug combination improves glucose control in Type 2 diabetes patientsRead the original story w/Photo

    Mar 2, 2016 | Medical News

    A multinational clinical trial led by UT Southwestern Medical Center and others found that injection of a new long-acting insulin combined with another drug improves glucose control in patients with Type 2 diabetes and, additionally, is associated with weight loss. The trial compared glucose control of participants receiving daily injections of either basal insulin glargine or IDegLira, which is a mixture of insulin degludec and liraglutide, a glucagon-like peptide 1 receptor agonist.

    Comment?

  20. Glucose Control for Patients with Type 2 DiabetesRead the original story

    Mar 1, 2016 | Health News Digest

    March. 1, 2016 - A multinational clinical trial led by UT Southwestern Medical Center and others found that injection of a new long-acting insulin combined with another drug improves glucose control in patients with Type 2 diabetes and, additionally, is associated with weight loss.

    Comment?